Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

Identification of cystatin SN as a novel biomarker for pancreatic cancer

Authors: Jie Jiang, Hui-Ling Liu, Zhi-Hao Liu, Si-Wei Tan, Bin Wu

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Cystatin SN (cystatin 1, CST1) is a member of the cystatin superfamily that inhibits the proteolytic activity of cysteine proteases. CST1 is a tumor biomarker that provides useful information for the diagnosis of esophageal, gastric, and colorectal carcinomas. However, the significance of CST1 in pancreatic cancer is unknown. The aim of this study was to assess whether CST1 is a potential biomarker for early diagnosis of malignant pancreatic neoplasms. Microarray analysis of mRNA extracted from pancreatic cancer and pancreatic normal tissues was performed. Bioinformatics revealed that CST1 was one of the highest expressed genes on the array in pancreatic cancer, compared with normal tissue. In addition, the upregulation of CST1 in pancreatic cancer and several pancreatic cancer cell lines was confirmed using real-time PCR (RT-PCR), immunohistochemistry, and Western blotting. Next, CST1 knockdown using siRNA reduced the expression of the proliferation-related proteins p-AKT and PCNA significantly, as well as colony formation and xenograft development in vitro. Consistent with this, CST1 mRNA overexpression was correlated closely with malignancy-associated proteins such as PCNA, cyclin D1, cyclin A2, and cyclin E in pancreatic cancer cell lines. In conclusion, our data suggest that CST1 might contribute to the proliferation of pancreatic cancer cells and could be a potential biomarker for the early detection of pancreatic cancer.
Literature
1.
2.
3.
Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31:13–22.CrossRefPubMed
4.
Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435–44.CrossRefPubMed
5.
Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.CrossRefPubMed
6.
Lah TT, Babnik J, Schiffmann E, Turk V, Skaleric U. Cysteine proteinases and inhibitors in inflammation: their role in periodontal disease. J Periodontol. 1993;64:485–91.PubMed
7.
Travis J, Potempa J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim Biophys Acta. 2000;1477:35–50.CrossRefPubMed
8.
Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113–35.CrossRefPubMed
9.
Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta. 1986;45:1363–74.PubMed
10.
Dickinson DP, Zhao Y, Thiesse M, Siciliano MJ. Direct mapping of seven genes encoding human type 2 cystatins to a single site located at 20p11.2. Genomics. 1994;24:172–5.CrossRefPubMed
11.
Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem. 1997;378:141–50.PubMed
12.
Dickinson DP, Thiesse M, Hicks MJ. Expression of type 2 cystatin genes CST1-CST5 in adult human tissues and the developing submandibular gland. DNA Cell Biol. 2002;21:47–65.CrossRefPubMed
13.
Choi EH, Kim JT, Kim JH, Kim SY, Song EY, Kim JW, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clin Chim Acta. 2009;406:45–51.CrossRefPubMed
14.
Yoneda K, Lida H, Endo H, Hosono K, Akiyama K, Takahashi H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol. 2009;35:33–40.PubMed
15.
Kim JT, Lee SJ, Kang MA, Park JE, Kim BY, Yoon DY, et al. Cystatin SN neutralizes the inhibitory effect of cystatin C on cathepsin B activity. Cell Death Dis. 2013;19(4):e974.CrossRef
16.
Chen YF, Ma G, Cao X, Luo RZ, He LR, He JH, et al. Overexpression of Cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma. BMC Surg. 2013;13:15.CrossRefPubMedPubMedCentral
17.
Lindahl P, Abrahamson M, Bjork I. Interaction of recombinant human cystatin C with the cysteine proteinases papain and actinidin. Biochem J. 1992;281:49–55.CrossRefPubMedPubMedCentral
18.
Isemura S, Saitoh E, Sanada K, Minakata K. Identification of full-sized forms of salivary (S-type) cystatins (cystatin SN, cystatin SA, cystatin S, and two phosphorylated forms of cystatin S) in human whole saliva and determination of phosphorylation sites of cystatin S. J Biochem. 1991;110:648–54.CrossRefPubMed
19.
Thiesse M, Millar SJ, Dickinson DP. The human type 2 cystatin gene family consists of eight to nine members, with at least seven genes clustered at a single locus on human chromosome 20. DNA Cell Biol. 1994;13:97–116.CrossRefPubMed
20.
Henskens YM, Veerman EC, Nieuw Amerongen AV. Cystatins in health and diseases. Biol Chem Hoppe Seyler. 1996;37:71–86.
21.
Buttle DJ, Burnett D, Abrahamson M. Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest. 1990;50:509–16.CrossRefPubMed
22.
Dickinson DP, Thiesse M, Dempsey LD, Millar SJ. Genomic cloning, physical mapping, and expression of human type 2 cystatin genes. Crit Rev Oral Biol Med. 1993;4:573–80.CrossRefPubMed
23.
Burka T, van der Noen H, Patil S. Cysteine proteinase inhibitor in cultured human medullary thyroid carcinoma cells. Lab Invest. 1992;66:691–700.
24.
Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christenser IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 2000;6:505–11.PubMed
25.
Sotiropoulou G, Anisowicz A, Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem. 1997;272:903–10.CrossRefPubMed
26.
Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126:869–81.CrossRefPubMed
27.
Vigneswaran N, Wu J, Zacharias W. Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis. Oral Oncol. 2003;39:559–68.CrossRefPubMed
28.
Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin Am. 2002;16:37–52.CrossRef
29.
Kokhanenko NI, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, et al. Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol. 2001;47:294–7.PubMed
30.
Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer. 1994;70:487–92.CrossRefPubMedPubMedCentral
31.
Ventrucci M, Ubalducci GM, Cipolla A, Panella MA, Ligabue A. Serum CA 242: the search for a valid marker of pancreatic cancer. Clin Chem Lab Med. 1998;36:179–84.CrossRefPubMed
Metadata
Title
Identification of cystatin SN as a novel biomarker for pancreatic cancer
Authors
Jie Jiang
Hui-Ling Liu
Zhi-Hao Liu
Si-Wei Tan
Bin Wu
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-3033-3

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue

Research Article

RETRACTED ARTICLE: CIP2A mediates prostate cancer progression via the c-MYC signaling pathway

Research Article

Expression of serum let-7c, let-7i, and let-7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease

Review

Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways

Research Article

Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation

Research Article

Involvement of NEDD9 in the invasion and migration of gastric cancer

Research Article

MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an 18F labeled RGD-based probe in SKOV-3 xenograft-bearing mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits